ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,040.53
0.00%
Dow Jones
44,544.66
0.00%
US Dollar vs MXN
21.00231
2.53%
Brent Oil
76.675
0.42%
Bitcoin
94,574.67
-3.20%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Italia
  5. BIT

  6. Sanofi (1SAN) Cotización

Sanofi

Sanofi (1SAN)

BIT
104.28
0.64
( 0.62% )
Actualizado: 08:05:15
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
104.28
Postura de Compra
104.12
Postura de Venta
104.22
Volume Operado de la Acción
456
103.82 Rango del Día 104.28
84.98 Rango de 52 semanas 107.96
Capitalización de Mercado [m]
130.625B
Precio Anterior
103.64
Precio de Apertura
103.82
Hora
30
@
104.28
Última hora de negociación
07:43:59
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
862
Acciones en circulación
1,252,640,466
Rendimiento del Dividendo
3.61%
Ratio Precio/Utilidad
24.20
Beneficio por acción (BPA)
4.31
turnover
43.07B
Beneficio neto
5.4B

Acerca de Sanofi

Sector
Health & Allied Services,nec
Industria
Pharmaceutical Preparations
Sitio web
www.sanofi.com
Sede
Paris, Paris, Fra
Fundado
1994
Sanofi is listed in the Health & Allied Services sector of the Italian Stock Exchange with ticker 1SAN. The last closing price for Sanofi was 103.64 €. Over the last year, Sanofi shares have traded in a share price range of 84.98 € to 107.96 €.

Sanofi currently has 1,252,640,466 shares in issue. The market capitalisation of Sanofi is 129.82 € billion. Sanofi has a price to earnings ratio (PE ratio) of 24.20.

1SAN Últimas noticias

Más noticias

Communiqué de presse : Sanofi annonce un rachat d'actions à L'Oréal

Communiqué de presse : Sanofi annonce un rachat d'actions à L'Oréal Sanofi annonce un rachat d'actions à L'Oréal Paris, le 3 février 2025. Sanofi annonce aujourd'hui l'acquisition de...

8 horas hace
UK Regulatory

Press Release: Sanofi announces buy back of shares from L’Oréal

Press Release: Sanofi announces buy back of shares from L’Oréal Sanofi announces buy back of shares from L’Oréal Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its...

8 horas hace
UK Regulatory

Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Sarclisa is the first anti-CD38 treatment...

31 Enero 2025
UK Regulatory

Communiqué de presse : Sarclisa est le premier anti-CD38 approuvé en Chine pour le traitement du myélome multiple nouvellement diagnostiqué des patients non éligibles à une greffe

Communiqué de presse : Sarclisa est le premier anti-CD38 approuvé en Chine pour le traitement du myélome multiple nouvellement diagnostiqué des patients non éligibles à une greffe Sarclisa est le...

31 Enero 2025
UK Regulatory

Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025

Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance...

30 Enero 2025
UK Regulatory

Communiqué de presse : Croissance des ventes de 10,3% au T4. Objectif du BNPA des activités de 2024 dépassé. Fort rebond du BNPA des activités attendu en 2025

Communiqué de presse : Croissance des ventes de 10,3% au T4. Objectif du BNPA des activités de 2024 dépassé. Fort rebond du BNPA des activités attendu en 2025 Sanofi: Croissance des ventes de...

30 Enero 2025
UK Regulatory

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Decembre 2024

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Decembre 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II...

29 Enero 2025
UK Regulatory

Sanofi: Information concerning the total number of voting rights and shares - December 2024

Sanofi: Information concerning the total number of voting rights and shares - December 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L...

29 Enero 2025
UK Regulatory

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma Sarclisa approved...

22 Enero 2025
UK Regulatory

Communiqué de presse : Approbation du Sarclisa dans l’UE – premier anti-CD38 en association avec le schéma VRd de référence pour le traitement du myélome multiple nouvellement diagnostiqué de l’adulte non éligible à une greffe

Communiqué de presse : Approbation du Sarclisa dans l’UE – premier anti-CD38 en association avec le schéma VRd de référence pour le traitement du myélome multiple nouvellement diagnostiqué de...

22 Enero 2025
UK Regulatory
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
13.263.22708374579101.02104.6100.31121102.54297895DE
411.3712.237649338192.91104.692.9168899.54863309DE
127.988.2866043613796.3104.687.4886293.9632737DE
268.158.4781025694496.13107.9687.4878797.31437366DE
5216.5818.90535917987.7107.9684.9885093.60251773DE
15611.312.153151215392.98107.9676.3692491.89144255DE
26016.7719.163524168787.51107.9668146087.87058644DE

1SAN - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Sanofi?
El precio actual de las acciones de Sanofi es 104.28 €
¿Cuántas acciones de Sanofi están en circulación?
Sanofi tiene 1,252,640,466 acciones en circulación
¿Cuál es la capitalización de mercado de Sanofi?
La capitalización de mercado de Sanofi es EUR 129.82B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Sanofi?
Sanofi ha negociado en un rango de 84.98 € a 107.96 € durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Sanofi?
El ratio precio/beneficio de Sanofi es 24.2
¿Cuál es el ratio de efectivo a ventas de Sanofi?
El ratio de efectivo a ventas de Sanofi es 3.03
¿Cuál es la moneda de reporte de Sanofi?
Sanofi presenta sus resultados financieros en EUR
¿Cuál es el último ingresos anual de Sanofi?
El último ingresos anual de Sanofi es EUR 43.07B
¿Cuál es el último beneficio anual de Sanofi?
El último beneficio anual de Sanofi es EUR 5.4B
¿Cuál es la dirección registrada de Sanofi?
La dirección registrada de Sanofi es 46, AVENUE DE LA GRANDE ARMEE, PARIS, PARIS, 75017
¿Cuál es la dirección del sitio web de Sanofi?
La dirección del sitio web de Sanofi es www.sanofi.com
¿En qué sector industrial opera Sanofi?
Sanofi opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
WIVN26iVision Tech SpA
0.48 €
(20.00%)
18.1k
NTWNetweek SpA
0.088 €
(18.92%)
1.14M
PORPortobello SPA
2.23 €
(10.40%)
25.05k
SFTSoftlab SPA
0.835 €
(8.44%)
4.55k
1PLDPrologis Inc
113.20 €
(8.08%)
28
WRDF25Redelfi SpA
1.25 €
(-17.75%)
2k
WAMB26Ambromobiliare SpA
0.033 €
(-17.29%)
10k
WTFINTrevi Finanziaria Industriale Spa
0.60 €
(-16.67%)
8
WABTGAlfio Bardolla Training Group Spa
0.127 €
(-15.33%)
39.01k
TDTrenDevice Spa
0.109 €
(-14.84%)
289.5k
TITTelecom Italia SpA
0.2668 €
(0.49%)
120.02M
STLAMStellantis NV
12.16 €
(-6.19%)
21.28M
SPMSaipem Spa
2.30 €
(-2.91%)
17.97M
FDAFidia
0.0158 €
(-1.25%)
17.04M
ENELEnel Spa
6.873 €
(0.06%)
14.89M

Discusión

Ver feed completo
doc2016 doc2016 3 minutos hace
opensource? opensource and linux.......jensen's keynote speech prominently discussed msft and wls........windows linux subsystem.
deaf ears or trying to ignore important words in order to maximize the impact of pr/propaganda attack against nvidia and the west?
but gosh if the tom's ha
NVDA
toohot toohot 4 minutos hace
I second that. Helped with all kinds of pain for me too. Good post. Thanks for sharing!


ME: "I can attest firsthand to the fact that ActiPatch is a life-saver when it comes to relief of the debilitating pain of Lumbosacral and Cervical Radiculopathy".


BIEL
ProfitChaser ProfitChaser 4 minutos hace
This one has been on top of the communications lately. Most recent tweet below and also a PR out this week

o.
KRTLBIOTECH OTC:KRTL
@KRTLBiotech
$KRTL has strategically positioned itself in Bolivia because it has an abundant biodiversity, which could be a valuable
API KRTL
RobotDroid RobotDroid 4 minutos hace
Nobody who really folllows this mute inept nonmanagement team of clown expects the 10Q to be filed on time. Just like the ASM, it could be any time in the next 12 months...or later.
NWBO
LexTrader LexTrader 5 minutos hace
It’s called being preemptive . If we stop the drug from coming across the southern border, where do you think the drugs will start flowing from?
Canada would become the path of least resistance, so Trump is attempting to strengthen their resolve to stiffen enforcement of the northern border
alertmeipp alertmeipp 5 minutos hace
Logic says if they were better than ENTA, they would have presented it? Presenting it would 1) to discourage others to partner with Enta 2) please their shareholders, not like they would be looking to this out. Do you see how keeping that piece of data would serve any competitive advantage ?
ENTA
doomed doomed 5 minutos hace
Do not forget to scarf up more shares today… bargain at these prices!
Smart to cop before share prices tumble.
TLRY
zab zab 5 minutos hace
I remember I had a few truly professional jobs in my lifetime, and one boss took me aside. Told me directly, that when I come to work that I dress appropriately. If you want me to respect you, then respect the company you are working for. The next morning, I was in a shirt and tie, and my jacket was
XMaster2023 XMaster2023 6 minutos hace
Last chance sub .30. Let’s Go!
NWBO
stockprofitter stockprofitter 6 minutos hace
Buy the dip
FNMA
ColdDarkHole ColdDarkHole 7 minutos hace
Most all of us are deep red anyway, and the company is broke. It cant really get any worse. So no, it wont matter.
NB
europa7 europa7 7 minutos hace
9 Themes We're Excited About for 2025 ~ Hive Mind Capital
January 10, 2025
https://www.hivemind.capital/content/9-themes-were-excited-about-for-2025

1. AI agents as the zero to one moment for economic activity on web3
2. Bitcoin native defi
3. When AI Agent
HBARUSD
manibiotech manibiotech 7 minutos hace
Hey do you have any facts against the original post ??
I guess not 
NWBO
Jetmek_03052 Jetmek_03052 8 minutos hace
Moronic.

I'm out at $6.15 a share.

That means you will NEVER be out and will be a perpetual bag holder.
DBMM
100lbStriper 100lbStriper 8 minutos hace
wow, i'm actually surprised!!! would of thought it would be at least good for that price.
NLST
Maxthedog Maxthedog 8 minutos hace
The question is does the API be affected by tariffs?
Well did the approval of generic Vyvanse affect the price?
Did the launch of generic Vyvanse affect the price?
Did the 3 drugs that went onto the market affect the price?
No,no,no,no. So is doesn’t make a difference in
API
pos_stock_hoarder pos_stock_hoarder 8 minutos hace
I think that we should also look for more friendly foreigners who want to help us out! Like these guys. Every little bit helps!
https://pbs.twimg.com/media/Gi0TGrpWUAI_fDx?format=jpg&name=900x900
againstallodds againstallodds 8 minutos hace
Inflation is setting for everyone in North America

Thanks DJT
DJT
AyaStocks AyaStocks 8 minutos hace
$ADIA Officially Enters $15.1 Billion Global Stem Cell Market with Domestic Treatments by Successful Opening of First Florida Location
https://www.globenewswire.com/news-release/2025/02/03/3019534/0/en/Adia-Nutrition-Officially-Enters-15-1-Billion-Global-Stem-Cell-Market-with-Domestic-Treatme
ADIA
JusticeWillWin JusticeWillWin 8 minutos hace
💥🚀LATEST $COOP price targets==>DEUTSCHE BANK:$132, UBS:$122, Piper Sandler:$120, JMP Securities:$115, Wedbush:$115, Barclays:$111, Compass Point:$110, KBW:$105
COOP
AyaStocks AyaStocks 8 minutos hace
$ADIA Officially Enters $15.1 Billion Global Stem Cell Market with Domestic Treatments by Successful Opening of First Florida Location
https://www.globenewswire.com/news-release/2025/02/03/3019534/0/en/Adia-Nutrition-Officially-Enters-15-1-Billion-Global-Stem-Cell-Market-with-Domestic-Treatme
ADIA
Tahoe2468 Tahoe2468 8 minutos hace
https://www.facebook.com/share/v/12Kxb1ikVzK/?mibextid=wwXIfr 

Wish I didn't drop out of Spanish 1 in high school 😂😂😂
KRTL
doughnuthole doughnuthole 8 minutos hace
Far as it looks like to me. There is no ta computer share is not the TA and neither is that other group y'all sent me to. It looks like computer share is the TA on record but when you call them on the phone they say they are no longer the TA
HGilS HGilS 9 minutos hace
HUGE SPREAD - interesting which way it goes
ELTP

Su Consulta Reciente

BIT
1SAN
Sanofi
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios